186 related articles for article (PubMed ID: 24915115)
1. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.
Mandema JW; Zheng J; Libanati C; Perez Ruixo JJ
J Clin Endocrinol Metab; 2014 Oct; 99(10):3746-55. PubMed ID: 24915115
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.
Nicolopoulos K; Moshi MR; Stringer D; Ma N; Jenal M; Vreugdenburg T
Arch Osteoporos; 2023 Jan; 18(1):18. PubMed ID: 36624318
[TBL] [Abstract][Full Text] [Related]
3. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Tutaworn T; Nieves JW; Wang Z; Levin JE; Yoo JE; Lane JM
Osteoporos Int; 2023 Mar; 34(3):573-584. PubMed ID: 36602607
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis.
Miyoshi A; Kameda H; Nagai S; Nakamura A; Miya A; Takase T; Atsumi T; Miyoshi H
J Diabetes Investig; 2021 Jul; 12(7):1293-1300. PubMed ID: 33141482
[TBL] [Abstract][Full Text] [Related]
5. Prevention and treatment of postmenopausal osteoporosis.
Tella SH; Gallagher JC
J Steroid Biochem Mol Biol; 2014 Jul; 142():155-70. PubMed ID: 24176761
[TBL] [Abstract][Full Text] [Related]
6. Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study.
Jeka S; Dokoupilová E; Kivitz A; Żuchowski P; Vogg B; Krivtsova N; Sekhar S; Banerjee S; Schwebig A; Poetzl J; Body JJ; Eastell R
J Bone Miner Res; 2024 Apr; 39(3):202-210. PubMed ID: 38477751
[TBL] [Abstract][Full Text] [Related]
7. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.
Austin M; Yang YC; Vittinghoff E; Adami S; Boonen S; Bauer DC; Bianchi G; Bolognese MA; Christiansen C; Eastell R; Grauer A; Hawkins F; Kendler DL; Oliveri B; McClung MR; Reid IR; Siris ES; Zanchetta J; Zerbini CA; Libanati C; Cummings SR;
J Bone Miner Res; 2012 Mar; 27(3):687-93. PubMed ID: 22095631
[TBL] [Abstract][Full Text] [Related]
8. Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis.
Hong N; Shin S; Lee S; Rhee Y
Osteoporos Int; 2023 Dec; 34(12):2059-2067. PubMed ID: 37596432
[TBL] [Abstract][Full Text] [Related]
9. Effect of Osteoporosis Treatments on Osteoarthritis Progression in Postmenopausal Women: A Review of the Literature.
Ho WC; Chang CC; Wu WT; Lee RP; Yao TK; Peng CH; Yeh KT
Curr Rheumatol Rep; 2024 May; 26(5):188-195. PubMed ID: 38372871
[TBL] [Abstract][Full Text] [Related]
10. Denosumab in postmenopausal osteoporosis: what the clinician needs to know.
Lewiecki EM
Ther Adv Musculoskelet Dis; 2009 Feb; 1(1):13-26. PubMed ID: 22870424
[TBL] [Abstract][Full Text] [Related]
11. Prevention and treatment of corticosteroid-induced osteoporosis.
Iwamoto J; Takeda T; Sato Y
Yonsei Med J; 2005 Aug; 46(4):456-63. PubMed ID: 16127768
[TBL] [Abstract][Full Text] [Related]
12. Effects of Different Types of Exercise on Bone Mineral Density in Postmenopausal Women: A Systematic Review and Meta-analysis.
Kemmler W; Shojaa M; Kohl M; von Stengel S
Calcif Tissue Int; 2020 Nov; 107(5):409-439. PubMed ID: 32785775
[TBL] [Abstract][Full Text] [Related]
13. Skeletal response to teriparatide in real-life setting: effects of age, baseline bone density and prior denosumab use.
Konings V; Laurent MR; Janssens S; Dupont J; Gielen E; Dejaeger M
Acta Clin Belg; 2023 Dec; 78(6):446-451. PubMed ID: 37466144
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Bone Mineral Density Changes in Kidney Transplant Recipients Treated with Denosumab: A Retrospective Study with Nonequivalent Control Group.
Fassio A; Andreola S; Gatti D; Pollastri F; Gatti M; Fabbrini P; Gambaro G; Ferraro PM; Caletti C; Rossini M; Viapiana O; Bixio R; Adami G
Calcif Tissue Int; 2024 May; ():. PubMed ID: 38730099
[TBL] [Abstract][Full Text] [Related]
15. Three-year effect of bisphosphonates on bone mineral density after denosumab withdrawal: observations from a real-world study.
Farias V; Jerkovich F; Barragán AM; Pereyra A; Pernas MG; Abdala R; Longobardi V; Zanchetta MB
JBMR Plus; 2024 Jun; 8(6):ziae044. PubMed ID: 38764789
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis.
Yamaguchi Y; Morita T; Kumanogoh A
Rheumatol Adv Pract; 2020; 4(1):rkaa008. PubMed ID: 32373775
[TBL] [Abstract][Full Text] [Related]
17. Current and emerging therapies for the treatment of osteoporosis.
Waalen J
J Exp Pharmacol; 2010; 2():121-34. PubMed ID: 27186098
[TBL] [Abstract][Full Text] [Related]
18. Optimization of the dosage regimen of zoledronic acid with a kinetic-pharmacodynamic model and exposure-response analysis.
Wang H; Liu Q; Jiang M; Song C; Liu D
Front Pharmacol; 2023; 14():1089774. PubMed ID: 37829305
[No Abstract] [Full Text] [Related]
19. Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis.
Zhou Z; Chen C; Zhang J; Ji X; Liu L; Zhang G; Cao X; Wang P
Int J Clin Exp Pathol; 2014; 7(5):2113-22. PubMed ID: 24966919
[TBL] [Abstract][Full Text] [Related]
20. Network Meta-Analysis of Pharmacological Agents for Osteoporosis Treatment and Fracture Prevention.
Yang XC; Deng ZH; Wen T; Luo W; Xiao WF; Zhao RB; Li YS
Cell Physiol Biochem; 2016; 40(3-4):781-795. PubMed ID: 27915335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
